AB 766

This bill creates program review and reporting requirements for the

Prescription Drug Monitoring Program (PDMP) administered by the Controlled

Substances Board. Beginning in 2017, the bill requires the board to conduct an

annual review of the PDMP to evaluate the actual program outcomes compared with

projected outcomes. That review must include an evaluation of the satisfaction with

the PDMP of pharmacists, pharmacies, practitioners, and other users of the PDMP

and the PDMP's impact on referrals of pharmacists, pharmacies, and practitioners

to relevant boards for discipline and to law enforcement agencies for investigation

and prosecution. The bill requires the board to report the results of its annual

program review to the Department of Safety and Professional Services. The bill

sunsets the program review requirement after the program review is conducted in

2020.

Also beginning in 2017, the bill requires the board to submit a report to DSPS

on an annual basis that includes all of the following:

1. An assessment of the trends and changes in the use of monitored prescription

drugs in Wisconsin.

2. The number of practitioners, by profession, and pharmacies submitting

records to the board under the PDMP.

3. A description of the number, frequency, and nature of certain submissions

of information to the PDMP by law enforcement agencies, including notices of

suspected violations of controlled substances laws, opioid-related drug overdoses,

deaths as a result of using a narcotics, and reports of stolen controlled-substance

prescriptions. This reporting requirement becomes effective only if 2015 Assembly

Bill 365 becomes law.

4. A description of the number, frequency, and nature of requests for disclosure

of records generated under the PDMP.

5. The number of individuals receiving prescription orders from five or more

practitioners or having monitored prescription drugs dispensed by five or more

pharmacies within the same 90-day period.

6. The number of individuals receiving daily morphine milligram equivalents

of one to 19 milligrams, 20 to 49 milligrams, 50 to 99 milligrams, and 100 or more

milligrams.

7. The number of individuals to whom both opioids and benzodiazepines were

dispensed within the same 90-day period.